Antengene Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day
ATG-008 (dual mTORC1/2 inhibitor) continued showing strong clinical activities in the Phase II program, with promising efficacy data in cervical cancer patients compared to benchmarks.
- ATG-008 (dual mTORC1/2 inhibitor) continued showing strong clinical activities in the Phase II program, with promising efficacy data in cervical cancer patients compared to benchmarks.
- The event will also include presentations and discussion with three well-known clinical experts from leading medical centers in the U.S. and Australia.
- Everyone at Antengene has resolute dedication to our mission and these early data affirm that we are delivering."
- The Chinese session will be held in-person at the Antengene Shanghai Office and virtually at 8:30 AM, November 17, 2023, Beijing Time.